Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
February 18, 2008
FDA allowing info on non FDA approved uses? A bonus for Pharma but a nightmare for insurers.
Analysis of: F.D.A. Seeks to Broaden Range of Use for Drugs | www.nytimes.com
Author: GLG Expert Contributor
As an oncologist we are aware of a drugs efficacy in conditions other than what it has been approved. Avastin in breast cancer; Nexavar and Erbitux in lung cancer, Taxotere in sarcomas. This list would be voluminous and would be a real benefit for patients BUT.......
February 15, 2008
"Targeted" approach in both Ovarian and endometrial tumors? Very interesting and potentially effective!
Analysis of: Æterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers | www.pipelinereview.com
Author: GLG Expert Contributor
Targeting gynecologic tumors with a "hormone" attached to an effective chemotherapeutic agent.
February 14, 2008
Rituxan: Another use for Vitamin R???
Analysis of: B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis | content.nejm.org
Author: GLG Expert Contributor
Very preliminary but if a larger study is confirmatory, and even before in the community, this agent will be used in MS.
February 14, 2008
Avastin (Genentech, Roche) in Breast Cancer: The Second Time is a Charm with the FDA???
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
Author: GLG Expert Contributor
"Genentech said Tuesday that a new clinical trial had shown that its best-selling drug Avastin was effective in treating breast cancer, a finding that could increase the chances that the product will be approved for that use."
February 12, 2008
Low Molecular Weight Heparins (LMWH): a windfall!!
Analysis of: Problems in Blood Drug Lead to Halt by Factory | www.nytimes.com
Author: GLG Expert Contributor
If there is a production delay in "standard" heparin, it will open the door for LMWH preparations. Which ones? Sanofi-Aventis's Lovenox
February 11, 2008
Are second (tandem) transplants dead in MM and what does it mean to PHARMA
Analysis of: Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
Thalidomide post single stem cell transplant is as good as two transplants back to back (tandem.)
February 11, 2008
Hair follicle analysis directing cancer care- What if the chemo or mother nature leaves you bald???
Analysis of: Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development | www.foxbusiness.com
Author: GLG Expert Contributor
Analysis of RNA obtained from hair follicles can be used to guide drug development and therapy
February 8, 2008
Diabetes Mellitus Trial: Disclaimer: I am not a diabetes expert but I have been a physician x 39 years....
Analysis of: Diabetes Study Partially Halted After Deaths | www.nytimes.com
Author: GLG Expert Contributor
".... a major federal study of more than 10,000 middle-aged and older people with Type 2 diabetes (DM) has found that lowering blood sugar actually increased their risk of death, researchers reported Wednesday."
February 5, 2008
GlaxoSmithKline (GSK) oral Topotecan: Impact? Use?
Analysis of: GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer | www.pipelinereview.com
Author: GLG Expert Contributor
An oral version of Topotecan that can be used 2nd line in SCLCA. Impact?
February 4, 2008
Velcade: 1st line indication probable, but is it really better and easier??
Analysis of: FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma | www.pipelinereview.com
Author: GLG Expert Contributor
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) is pressing for approval of Velcade in a first line rather than second line + setting. This would definitely increase sales

Previous Page : 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 Next161 to 170 of 450

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440